Peptide
Rapastinel
SaveA tetrapeptide (GLYX-13) that acts as an NMDA receptor modulator with glycine-site partial agonist activity, developed as a rapid-acting antidepressant.
Quick verdict
Phase II data showed rapid antidepressant effects within hours. Phase III trials failed to meet primary endpoints and development was discontinued.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Phase II trial showed antidepressant effects at 2 hours post-dose lasting ~7 days. Three phase III trials failed to separate from placebo. Allergan discontinued development.
Benefits
- Rapid antidepressant effect within hours in phase II
- NMDA modulation without dissociative side effects
- Novel mechanism of action
Dosage notes
Phase II: single IV dose of 5–10 mg/kg. Not commercially available.
Side effects
- Generally well tolerated in trials
- Headache
- Dizziness
- Dissociation not observed at therapeutic doses
Who should be cautious
Clinical development discontinued after phase III failure. Not commercially available.
What this page cannot tell you
Promising mechanism but failed in confirmatory trials. Reasons for phase III failure are debated.
Leaderboard scores
- Mood30
- Anxiety20
Write a review
Sign in to write a review.